Suggested remit: To appraise the clinical and cost effectiveness of zuranolone within its marketing authorisation for treating severe postnatal depression.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6431
Provisional Schedule
- Expected publication:
- 15 October 2025
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Bristol Technology Assessment Group, University of Bristol
Stakeholders
- Companies sponsors
- Biogen (zuranolone)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action on Postpartum Psychosis
- Association for Post Natal Illness
- Association of Mental Health Providers
- Bipolar UK
- C.A.L.M
- Child Bereavement UK
- Depression UK
- Maternal Mental Health Alliance
- Mental Health Foundation
- Mental Health Matters
- MIND
- National Childbirth Trust
- PANDAS
- PAPYRUS
- Race Equality Foundation
- Rethink
- Sands - Stillbirth and neonatal death charity
- SANE
- South Asian Health Foundation
- Specialised Healthcare Alliance
- The Matthew Trust
- WISH - A Voice for women's mental health
- Professional groups
- British Association for Counselling and Psychotherapy
- British Association for Psychopharmacology
- British Association of Behavioural and Cognitive Psychotherapies
- British Association of Occupational Therapists and College of Occupational Therapists
- British Association of Social Workers
- British Geriatrics Society
- British Neuropsychiatry Association
- British Psychoanalytic Council
- British Psychological Society
- British Psychotherapy Foundation
- College of Mental Health Pharmacy
- Counsellors and Psychotherapists in Primary Care
- Health and Care Professions Council
- Mental Health Nurses Association
- Primary Care Mental Health Education
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Obstetricians and Gynaecologists
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Psychiatrists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine)
- Amneal Pharma Europe (duloxetine, paroxetine)
- Arristo Pharma (quetiapine)
- AstraZeneca (quetiapine)
- Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline and venlafaxine)
- Chiesi (venlafaxine)
- Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine)
- Creo Pharma (lofepramine and trazodone)
- Dexcel Pharma (venlafaxine)
- Dr Reddys Labs (duloxetine, fluoxetine and sertraline)
- Fontus Heath (quetiapine)
- GlaxoSmithKline (paroxetine)
- HBS Healthcare (duloxetine)
- Kyowa Kirin (phenelzine)
- Lilly UK (duloxetine and fluoxetine)
- Lundbeck (citalopram, escitalopram, vortioxetine)
- Lupin (sertraline)
- Marlborough (doxepin)
- Merck Sharp & Dohme (mirtazapine)
- Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine)
- Par Laboratories Europe (fluoxetine)
- Pfizer (reboxetine, sertraline and venlafaxine)
- Rivopharm (citalopram, trazodone)
- Sandoz (citalopram, paroxetine and quetiapine)
- Servier (agomelatine)
- SilverCloud (Space from Depression)
- Sun Pharmaceuticals (sertraline and venlafaxine)
- Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine)
- Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine)
- Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Council for Wales
- Care Quality Commission
- Department of Health - Northern Ireland
- Gofal
- Hafal
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- MIND Cymru
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Social Care Institute for Excellence
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Campbell Collaboration Social Welfare Group
- Careif
- Critical Psychiatry Network
- Genomics England
- Health Services Research Unit, Department of Public Health, University of Oxford
- Institute of Psychiatry
- Joseph Rowntree Foundation
- MRC Clinical Trials Unit
- National Institute for Health Research
- National Primary Care Research & Development Centre
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 August 2025 | Committee meeting |
| 09 January 2025 | Invitation to participate |
| 11 November 2024 (14:00) | Scoping workshop |
| 16 September 2024 - 14 October 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6431 |
| 16 September 2024 | In progress. Scoping commencing |
| 07 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual